Biologics in Dermatology: An Integrated Review.
The advent of biologics in dermatologic treatment armentarium has added refreshing dimensions, for it is a major breakthrough. Several agents are now available for use. It is therefore imperative to succinctly comprehend their pharmacokinetics for their apt use. A concerted endeavor has been made to...
| Publicado en: | Indian Journal of Dermatology Vol. 59; no. 5; pp. 425 - 442 |
|---|---|
| Autores principales: | , , |
| Formato: | review Journal Article |
| Publicado: |
Wolters Kluwer India Pvt Ltd
Sep/Oct2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103888651&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 103888651 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00195154 259H jtl: Indian Journal of Dermatology issn: 00195154 maglogo: N pubinfo: dt: Sep/Oct2014 vid: 59 iid: 5 pid: 16919 pub: Wolters Kluwer India Pvt Ltd artinfo: ui: 103888651 98052887 10.4103/0019-5154.139859 NLM25284845 PMC4171908 103888651 ppf: 425 ppct: 17 formats: tig: atl: Biologics in Dermatology: An Integrated Review. aug: au: Sehgal, Virendra N. Pandhi, Deepika Khurana, Ananta affil: Dermato‑Venereology (Skin/VD) Center, Sehgal Nursing Home sug: subj: Biological Products Tumor Necrosis Factor Immunoglobulins, Intravenous Dermatology Infliximab Adalimumab Golimumab Rituximab Antibodies, Monoclonal Classification Pyoderma Gangrenosum Etanercept Connective Tissue Diseases Lupus Erythematosus, Systemic Epidermal Necrolysis, Toxic Sweet's Syndrome Pityriasis Rubra Pilaris Sarcoidosis Behcet's Syndrome Acquired Hyperostosis Syndrome Pemphigus ab: The advent of biologics in dermatologic treatment armentarium has added refreshing dimensions, for it is a major breakthrough. Several agents are now available for use. It is therefore imperative to succinctly comprehend their pharmacokinetics for their apt use. A concerted endeavor has been made to delve on this subject. The major groups of biologics have been covered and include: Drugs acting against TNF‑α, Alefacept, Ustekinumab, Rituximab, IVIG and Omalizumab. The relevant pharmacokinetic characteristics have been detailed. Their respective label (approved) and off-label (unapproved) indications have been defined, highlighting their dosage protocol, availability and mode of administration. The evidence level of each indication has also been discussed to apprise the clinician of their current and prospective uses. Individual anti‑TNF drugs are not identical in their actions and often one is superior to the other in a particular disease. Hence, the section on anti‑TNF agents mentions the literature on each drug separately, and not as a group. The limitations for their use have also been clearly brought out. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|